Polypeptide Generics Will Soon Break the Monopoly of Large Pharmaceutical Companies

 

Tablo reader up chevron

Polypeptide Generics Will Soon Break the Monopoly of Large Pharmaceutical Companies

It’s reported that the bioengineering skin can withstand the bombardment of live bullet at half speed, but there is a limit to its impact force. When the bullet reaches 329 m/s at full speed, it will penetrate the skin. Additionally, they have also found the sweat glands can produce a DCD polypeptide, which not only maintains the skin flora on stability but forms an ion channel on the membrane of pathogenic bacteria as well, enabling to prevent skin infections as the antibiotics.

Seen from the bulletproof skin and sweat polypeptide, modern peptides research has been continuously changing people’s daily life thoroughly throughout the history, especially for new drugs screening. In fact, in the late 1990s to the early 2000s, biopharmaceutical field was in a downturn period, and more capital was invested into gene-related products as well as other derivative medical products. However, the emergence of modern screening methods in peptides have brought great potential to new drugs development. In recent years, with the rapid advance inpeptide-related technology and equipment, a significant decline in peptide drug development and production costs is realized.

According to statistics, the approval listing rate for polypeptide generics is 10% higher thansmall molecule pharmaceutical compounds. Currently, there are about 10 to 20 peptide drug manufacturers worldwide, mainly in Europe; preparations are completely monopolized by large pharmaceutical companies.On the other hand,due to the geographical advantages, customer relations and policy barriers, large CMO companies basically monopolize the CMO business of patent peptide drugs, with market share over 80%. Main representative companies include Bachem, Lonza, Zealand, Merck and the like. For example, Merck’s venture capital firm has pumped money into the drug screening technology at NanoImaging, which mainly aims at the company’s TCM three-dimensional imaging method. Subsequently, this unique technique has been widely used in peptide drugs development by large biopharmaceutical companies.

Actually, some medium enterprises, such as Neopeptide, Creative Peptides and Biopeptide, are also proceeding with polypeptide drugs research. Taking Creative Peptides as an instance, it mainly focuses on the manufacturing of bioactive peptides, peptide synthesis as well as cosmetic peptides. Since the polypeptide sequence has become more complex and synthesis process is also increasingly difficult, it tries to apply new technique such as enzymatic peptide to the polypeptide drugs discovery, which can help it achieve large-scale peptide drug industrialization. These enterprises have gained awareness of accommodating themselves to meet modern technology requirements for polypeptide production.

Lately, an exciting news has attracted hot concerns from mass polypeptide companies, i.e., the patent of several polypeptide species is going to expire (include glatiramer for multiple sclerosis treatment, liraglutide for type II diabetes, goserelin for prostate cancer), which means polypeptide genericswill usher in promising development opportunities. Currently, the global market for polypeptide drugs has more than 20 billion dollars, accounting for about 2% of the total sharein pharmaceutical products, maintaining the growth rate of 10%. Without the barrier of technical patent, more polypeptide manufactures can benefit from the new technology, which will help promote the efficiency in clinical application of polypeptides drugs. And now the traditional ways of synthetic peptides have lagged behind, so that breaking the such monopoly under large pharmaceutical companies is able to improve polypeptide drugs use in wider therapeutic areas, with effective healthcare function, controlled molecular weight and high-level product quality.

As is known, many developing countries are still faced with technical challenges in chronic diseases, anti-tumor and rare diseases prevention & control, which always leads to higher risk for disease death. Moreover, high costs for these drugs is also a reason. Therefore, if they can use those monopolized polypeptide patents with lower costs, then more patients over the world can greatly benefit from modern biotechnology, and in return these large pharmaceutical companies with related patents will realize greater success as well, especially for the investment capital. Certainly, the biggest beneficiaries are mass customers because they have received effective treatment while reducing the financial burden.

This is the most important!

Comment Log in or Join Tablo to comment on this chapter...
~

You might like savage's other books...